AbbVie
1 North Waukegan Road
North Chicago
Illinois
60064
United States
Tel: 1-800-255-5162
Website: http://www.abbvie.com/
Email: customerservice@abbvie.com
About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.
Stock Symbol: ABBV
Stock Exchange: NYSE
We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.
Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.
1709 articles about AbbVie
-
AbbVie To Host First-Quarter Earnings Conference Call
4/7/2016
-
AbbVie CF Scholarship Now Accepting Applications From Students With Cystic Fibrosis For 2016-2017 Academic School Year
4/6/2016
-
AbbVie Partners With Nutrition Expert Joy Bauer To Launch New Resource For People With Often Under-Recognized GI Condition
4/5/2016
-
Samsung Bioepis Brings in Lawyers to Sue AbbVie in Biosimilars Push
4/4/2016
-
AbbVie Receives CHMP Positive Opinion For HUMIRA (adalimumab) For The Treatment Of Pediatric Patients, From Six Years Of Age, With Moderately To Severely Active Crohn's Disease
4/4/2016
-
AbbVie To Present Data On VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) And EXVIERA (dasabuvir tablets) And Investigational, Pan-Genotypic Regimen At The International Liver Congress 2016
3/30/2016
-
Regeneron, Sanofi's RA Drug Beats AbbVie's Blockbuster Humira in Phase III Study
3/14/2016
-
AbbVie To Present At Barclays Global Healthcare Conference
3/9/2016
-
AbbVie Coughs Up $595 Million+ for Boehringer Ingelheim's Psoriasis and Crohn’s Drugs
3/8/2016
-
AbbVie Announces New Dermatology Research From More Than 35 Presentations On HUMIRA (Adalimumab), Long-Term And Real-World Data At The American Academy of Dermatology 2016 Annual Meeting
3/2/2016
-
AbbVie, Boehringer Ingelheim Rumored to Be in Cancer-Partnership Talks
3/1/2016
-
AbbVie To Present At Cowen and Company 36th Annual Health Care Conference
2/29/2016
-
Nanotechnology Company Exicure Raises Over $42 Million from Bill Gates, AbbVie, Agilent and Others
2/26/2016
-
Enanta Pharmaceuticals, Inc. Announces CHMP Positive Opinion For AbbVie’s VIEKIRAX + EXVIERA® Without Ribavirin For The Treatment Of Chronic Hepatitis C In Genotype 1b Patients With Compensated Cirrhosis
2/26/2016
-
AbbVie Receives European Medicines Agency Orphan Drug Designation For Investigational Compound Venetoclax For The Treatment Of Acute Myeloid Leukemia (AML)
2/26/2016
-
AbbVie Receives CHMP Positive Opinion For VIEKIRAX (Ombitasvir/Paritaprevir/Ritonavir Tablets) + EXVIERA (Dasabuvir Tablets) Without Ribavirin For The Treatment Of Chronic Hepatitis C In Genotype 1b Patients With Compensated Cirrhosis (Child-Pugh A) In Eu
2/26/2016
-
Myriad Genetics Expands Strategic Research Collaboration With AbbVie
2/23/2016
-
Instead of AbbVie and Merck & Co., Gilead Should Fear Tiny Upstart Regulus
2/23/2016
-
AbbVie Declares Quarterly Dividend
2/18/2016
-
Only A Week After Bagging AbbVie R&D Deal, Synlogic Raises $40 Million Series B
2/17/2016